PREDNISONE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C21H26O5
Molecular Weight	358.4281
Optical Activity	UNSPECIFIED
Defined Stereocenters	6 / 6
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]3([H])[C@@]2([H])CCC4=CC(=O)C=C[C@]34C

InChI

InChIKey=XOFYZVNMUHMLCC-ZPOLXVRWSA-N

InChI=1S/C21H26O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-15,18,22,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,18+,19-,20-,21-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C21H26O5
Molecular Weight	358.4281
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	6 / 6
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202020s003lbl.pdf
Curator's Comment: description was created based on several sources, including

Prednisone is a synthetic anti-inflammatory glucocorticoid derived from cortisone. Prednisone is a corticosteroid indicated as an anti-inflammatory or immunosuppressive agent allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation; for the treatment of certain endocrine conditions; for palliation of certain neoplastic conditions. The pharmacological effects of prednisone which are due to its corticosteroid properties include: promotion of gluconeogenesis; increased deposition of glycogen in the liver; inhibition of the utilization of glucose; anti-insulin activity; increased catabolism of protein; increased lipolysis; stimulation of fat synthesis and storage; increased glomerular filtration rate and resulting increase in urinary excretion of urate (creatinine excretion remains unchanged); and increased calcium excretion. Depressed production of eosinophils and lymphocytes occurs, but erythropoiesis and production of polymorphonuclear leukocytes are stimulated. Inflammatory processes (edema, fibrin deposition, capillary dilatation, migration of leukocytes and phagocytosis) and the later stages of wound healing (capillary proliferation, deposition of collagen, cicatrization) are inhibited. Prednisone can stimulate secretion of various components of gastric juice. Suppression of the production of corticotropin may lead to suppression of endogenous corticosteroids. Prednisone has slight mineralocorticoid activity, whereby entry of sodium into cells and loss of intracellular potassium is stimulated. This is particularly evident in the kidney, where rapid ion exchange leads to sodium retention and hypertension. Prednisone is completely converted to the active metabolite prednisolone, which is further metabolized mainly in the liver and excreted in the urine as sulfate and glucuronide conjugates. The exposure of prednisolone is 4-6 fold higher than that of prednisone.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Glucocorticoid receptor 172 Target ID: CHEMBL2034 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202020s003lbl.pdf	Agonist 2678

Conditions

Condition	Modality	Highest Phase	Product
Atopic dermatitis 43 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202020s003lbl.pdf	Palliative	Approved 8429	RAYOS Approved Use RAYOS is a corticosteroid indicated as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation; for the treatment of certain endocrine conditions; for palliation of certain neoplastic conditions Launch Date 2012
Severe erythema multiforme (Stevens-Johnson syndrome) 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202020s003lbl.pdf	Palliative	Approved 8429	RAYOS Approved Use RAYOS is a corticosteroid indicated as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation; for the treatment of certain endocrine conditions; for palliation of certain neoplastic conditions Launch Date 2012
Congenital adrenal hyperplasia 41 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202020s003lbl.pdf	Palliative	Approved 8429	RAYOS Approved Use RAYOS is a corticosteroid indicated as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation; for the treatment of certain endocrine conditions; for palliation of certain neoplastic conditions Launch Date 2012
Crohn's disease 42 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202020s003lbl.pdf	Palliative	Approved 8429	RAYOS Approved Use RAYOS is a corticosteroid indicated as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation; for the treatment of certain endocrine conditions; for palliation of certain neoplastic conditions Launch Date 2012
Diamond-Blackfan anemia 3 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202020s003lbl.pdf	Palliative	Approved 8429	RAYOS Approved Use RAYOS is a corticosteroid indicated as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation; for the treatment of certain endocrine conditions; for palliation of certain neoplastic conditions Launch Date 2012
Aggressive lymphoma 3 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202020s003lbl.pdf	Palliative	Approved 8429	RAYOS Approved Use RAYOS is a corticosteroid indicated as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation; for the treatment of certain endocrine conditions; for palliation of certain neoplastic conditions Launch Date 2012

C_max

Value	Dose	Co-administered	Analyte	Population
15.4 μg/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/17925494	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:		PREDNISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED

AUC

Value	Dose	Co-administered	Analyte	Population
97 μg × h/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/17925494	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:		PREDNISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED

T_1/2

Value	Dose	Co-administered	Analyte	Population
3.85 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/17925494	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:		PREDNISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED

F_unbound

Value	Dose	Co-administered	Analyte	Population
50% EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/2199128			PREDNISONE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
100 mg 1 times / day multiple, oral Highest studied dose Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: https://doi.org/10.1016/B978-0-12-385157-4.00633-3 https://pubmed.ncbi.nlm.nih.gov/33663183	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://doi.org/10.1016/B978-0-12-385157-4.00633-3 https://pubmed.ncbi.nlm.nih.gov/33663183	Sources: https://doi.org/10.1016/B978-0-12-385157-4.00633-3 https://pubmed.ncbi.nlm.nih.gov/33663183
5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf Page: p. 92	unhealthy, adult n = 144 Health Status: unhealthy Age Group: adult Population Size: 144 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf Page: p. 92	Disc. AE: Vertigo, Abdominal pain upper... AEs leading to discontinuation/dose reduction: Vertigo (1%) Abdominal pain upper (1%) Gastroesophageal reflux disease (1%) Intestinal functional disorder (1%) Nausea (1%) Dizziness (1%) Aphasia (1%) Headache (1%) Renal pain (1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf Page: p. 92

AEs

AE	Significance	Dose	Population
Abdominal pain upper	1% Disc. AE	5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf Page: p. 92	unhealthy, adult n = 144 Health Status: unhealthy Age Group: adult Population Size: 144 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf Page: p. 92
Aphasia	1% Disc. AE	5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf Page: p. 92	unhealthy, adult n = 144 Health Status: unhealthy Age Group: adult Population Size: 144 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf Page: p. 92
Dizziness	1% Disc. AE	5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf Page: p. 92	unhealthy, adult n = 144 Health Status: unhealthy Age Group: adult Population Size: 144 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf Page: p. 92
Gastroesophageal reflux disease	1% Disc. AE	5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf Page: p. 92	unhealthy, adult n = 144 Health Status: unhealthy Age Group: adult Population Size: 144 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf Page: p. 92
Headache	1% Disc. AE	5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf Page: p. 92	unhealthy, adult n = 144 Health Status: unhealthy Age Group: adult Population Size: 144 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf Page: p. 92
Intestinal functional disorder	1% Disc. AE	5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf Page: p. 92	unhealthy, adult n = 144 Health Status: unhealthy Age Group: adult Population Size: 144 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf Page: p. 92
Nausea	1% Disc. AE	5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf Page: p. 92	unhealthy, adult n = 144 Health Status: unhealthy Age Group: adult Population Size: 144 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf Page: p. 92
Renal pain	1% Disc. AE	5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf Page: p. 92	unhealthy, adult n = 144 Health Status: unhealthy Age Group: adult Population Size: 144 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf Page: p. 92
Vertigo	1% Disc. AE	5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf Page: p. 92	unhealthy, adult n = 144 Health Status: unhealthy Age Group: adult Population Size: 144 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf Page: p. 92

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	11-beta-HSD2 27 11-beta-HSD1 12 P-gp 1537	P-gp 257 BCRP 75 MRP1 48 MRP4 32 MRP5 22 ABCC12 22 MRP2 111 MRP3 53

Drug as perpetrator

Target	Modality	Activity
ABCC12 22	inducer 1573 Sources: https://www.sciencedirect.com/science/article/pii/S0143400412002895 Page: -	no
BCRP 773	inducer 1573 Sources: https://www.sciencedirect.com/science/article/pii/S0143400412002895 Page: -	no
MRP1 172	inducer 1573 Sources: https://www.sciencedirect.com/science/article/pii/S0143400412002895 Page: -	no
MRP3 207	inducer 1573 Sources: https://pubmed.ncbi.nlm.nih.gov/15979871/ Page: -	no
MRP4 238	inducer 1573 Sources: https://www.sciencedirect.com/science/article/pii/S0143400412002895 Page: -	no
MRP5 48	inducer 1573 Sources: https://www.sciencedirect.com/science/article/pii/S0143400412002895 Page: -	no
P-gp 1650	inducer 1573 Sources: https://www.sciencedirect.com/science/article/pii/S0143400412002895 Page: -	no
MRP2 475	inducer 1573 Sources: https://pubmed.ncbi.nlm.nih.gov/15979871/ Page: -	yes

Drug as victim

Target	Modality	Activity
11-beta-HSD2 27	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349812/ Page: -	major
11-beta-HSD1 12	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349812/ Page: -	minor
P-gp 1537	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349812/ Page: -	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:8382	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:8382
ChemicalBook	CB44844383	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB44844383
ChemicalBook	CB6716222	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB6716222
MolPort	MolPort-001-740-041	https://www.molport.com/shop/molecule-link/MolPort-001-740-041
Selleck Chemicals	Prednisone	http://www.selleckchem.com/products/Prednisone.html
ZINC	ZINC000003875357	http://zinc15.docking.org/substances/ZINC000003875357
eMolecules	29549912	https://www.emolecules.com/cgi-bin/more?vid=29549912
eMolecules	29703823	https://www.emolecules.com/cgi-bin/more?vid=29703823
eMolecules	31411020	https://www.emolecules.com/cgi-bin/more?vid=31411020
eMolecules	494851	https://www.emolecules.com/cgi-bin/more?vid=494851

PubMed

Title	Date	PubMed
Cytogenetic studies in a patient with acute granulocytic leukemia of seven and one-half years duration.	1975 Nov	1058041
An unusual adverse reaction to self-medication with prednisone: an irrational crime during a fugue-state.	1976-1977	1052090
Spontaneous aortic rupture associated with chronic steroid therapy for rheumatoid arthritis in two cases.	1979 Feb	105598
Low-dose vincristine-associated bilateral vocal cord paralysis.	1999 Oct	10578547
Lamotrigine as prophylaxis against steroid-induced mania.	1999 Oct	10549692
Delayed generalized allergic reactions to corticosteroids.	2000	10894975
Acute neurotoxicity in children with B-lineage acute lymphoblastic leukemia (B-ALL) treated with intermediate risk protocols.	2000 Nov	11070476
Leucocytoclastic vasculitis and indinavir.	2000 Nov	11069541
Pulmonary mucosa-associated lymphoid tissue lymphoma in a patient with common variable immunodeficiency syndrome.	2001	11223743
Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers.	2001	11215697
Hodgkin's disease: clinical presentation and treatment.	2001	11191130
Current status of cytotoxic chemotherapy in hormone refractory prostate cancer.	2001 Feb	11223670
The usefulness of quantitative orbital magnetic resonance imaging in Graves' ophthalmopathy.	2001 Feb	11207635
Interstitial nephritis in patients with inflammatory bowel disease treated with mesalamine.	2001 Feb	11205659
Recalcitrant allergic contact dermatitis from azathioprine tablets.	2001 Feb	11205401
Idiopathic IgA nephropathy with segmental necrotizing lesions of the capillary wall.	2001 Feb	11168950
Interferon alfa 2b as maintenance therapy in poor risk diffuse large B-cell lymphoma in complete remission after intensive CHOP-BLEO regimens.	2001 Feb	11168516
Time course of 21-hydroxylase antibodies and long-term remission of subclinical autoimmune adrenalitis after corticosteroid therapy: case report.	2001 Feb	11158030
Adult Gaucher disease in association with primary malignant bone tumors.	2001 Feb 1	11169926
Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience.	2001 Feb 1	11157012
Sample size calculations for the two-sample problem using the multiplicative intensity model.	2001 Feb 28	11223901
Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial.	2001 Jan	11212161
Nocardia pleural empyema complicating anti-Jo1 positive polymyositis during immunoglobulin and steroid therapy.	2001 Jan	11196531
Plasmapheresis as an effective treatment for opsoclonus-myoclonus syndrome.	2001 Jan	11182286
Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.	2001 Jan	11180038
Persistent paraneoplastic neurologic syndrome after successful therapy of Hodgkin's disease.	2001 Jan	11168510
A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma.	2001 Jan	11168504
Multiple myeloma in elderly patients: presenting features and outcome.	2001 Jan	11168502
Immunosuppression as adjuvant therapy for biliary atresia.	2001 Jan	11150442
Biliary stricture secondary to donor B-cell lymphoma after orthotopic liver transplantation.	2001 Jan	11150426
Efficacy of parenteral methotrexate in refractory Crohn's disease.	2001 Jan	11136276
Diabetes insipidus and anterior pituitary insufficiency as presenting features of Wegener's granulomatosis.	2001 Jan	11136194
Cause of high variability in drug dissolution testing and its impact on setting tolerances.	2001 Jan	11113646
Dose-response analysis for radiotherapy delivered to patients with intermediate-grade and large-cell immunoblastic lymphomas that have completely responded to CHOP-based induction chemotherapy.	2001 Jan 1	11163493
Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group.	2001 Jan 1	11134196
High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial.	2001 Jan 15	11154216
Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial.	2001 Jan 16	11177313
Ethnic differences in clinical response to corticosteroid treatment of acute renal allograft rejection.	2001 Jan 27	11213064
Autologous bone marrow transplantation for aggressive non-Hodgkin's lymphoma: lessons learned and challenges remaining.	2001 Jan 3	11136829
Use of biological markers of airway inflammation to detect the efficacy of nurse-delivered asthma education.	2001 Jan-Feb	11174366
Depression or hypoactive delirium? A report of ciprofloxacin-induced mental disorder in a patient with chronic obstructive pulmonary disease.	2001 Jan-Feb	11150940

Patents

Sample Use Guides

In Vivo Use Guide

The initial dosage of RAYOS (prednisone) may vary from 5 to 60 mg per day depending on the specific disease entity being treated based on relative potency.

Route of Administration: Oral

In Vitro Use Guide

Peripheral blood lymphocytes (PBL) or peripheral CD4(+) and CD8(+) T cell subsets were cultured in the presence of prednisone (PDN) at 10(-3)-10(-12)M concentrations for 72, 96 and 120h. Apoptosis is clearly increased by PDN and the apoptotic effect of PDN is stronger on CD8(+) than on CD4(+) T lymphocytes.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:51:36 GMT 2023` Edited by `admin` on `Fri Dec 15 15:51:36 GMT 2023`
Record UNII	VB0R961HZT
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PREDNISONE

Official Name

English

17,21-Dihydroxypregna-1,4-diene-3,11,20-trione

Systematic Name

English

PREGNA-1,4-DIENE-3,11,20-TRIONE, 17,21-DIHYDROXY-

Systematic Name

English

PREDNISONE TABLETS [USP-RS]

Common Name

English

PREDNISONE INTENSOL

Brand Name

English

Prednisone [WHO-DD]

Common Name

English

SUPERCORTIL

Common Name

English

METACORTANDRACIN

Common Name

English

PREDNISONE [USP MONOGRAPH]

Common Name

English

PREDNISONE ANHYDROUS

Common Name

English

3EN3HG4WSW

Common Name

English

PREDNISONE [GREEN BOOK]

Common Name

English

NSC-10023

Code

English

prednisone [INN]

Common Name

English

DELTASONE

Brand Name

English

DEHYDROCORTISONE

Common Name

English

PREDNISONE [USP-RS]

Common Name

English

PREDNISONE [ORANGE BOOK]

Common Name

English

PREDNISONE [EP MONOGRAPH]

Common Name

English

PREDNISONE TABLETS

Common Name

English

PREDNISONE [IARC]

Common Name

English

PREDNISONE [VANDF]

Common Name

English

PREDNISONE [HSDB]

Common Name

English

PREDNISONE [MART.]

Common Name

English

PREDNISONE [MI]

Common Name

English

DECORTIN

Brand Name

English

PREDNISOLONE IMPURITY B [EP IMPURITY]

Common Name

English

Classification Tree Code System Code

WHO-ATC

H02AB07